Oral ketamine effects on dynamics of functional network connectivity in patients treated for chronic suicidality.

Journal: European archives of psychiatry and clinical neuroscience
Published Date:

Abstract

The underlying brain mechanisms of ketamine in treating chronic suicidality and the characteristics of patients who will benefit from ketamine treatment remain unclear. To address these gaps, we investigated temporal variations of brain functional synchronisation in patients with suicidality treated with ketamine in a 6-week open-label oral ketamine trial. The trial's primary endpoint was the Beck Scale for Suicide Ideation (BSS). Patients who experienced greater than 50% improvement in BSS scores or had a BSS score less than 6 at the post-treatment and follow-up (10 weeks) visits were considered responders and persistent responders, respectively. The reoccurring and transient connectivity pattern (termed brain state) from 29 patients (45.6 years ± 14.5, 15 females) were investigated by dynamic functional connectivity analysis of resting-state functional MRI at the baseline, post-treatment, and follow-up. Post-treatment patients showed significantly more (FDR-Q = 0.03) transitions among whole brain states than at baseline. We also observed increased dwelling time (FDR-Q = 0.04) and frequency (FDR-Q = 0.04) of highly synchronised brain state at follow-up, which were significantly correlated with BSS scores (both FDR-Q = 0.008). At baseline, persistent responders had higher fractions (FDR-Q = 0.03, Cohen's d = 1.39) of a cognitive control network state with high connectivities than non-responders. These findings suggested that ketamine enhanced brain changes among different synchronisation patterns and enabled high synchronisation patterns in the long term, providing a possible biological pathway for its suicide-prevention effects. Moreover, differences in cognitive control states at baseline may be used for precise ketamine treatment planning.

Authors

  • Zack Y Shan
    Thompson Institute, University of the Sunshine Coast, 12 Innovation Parkway, Birtinya, QLD, 4575, Australia. zshan@usc.edu.au.
  • Adem T Can
    Thompson Institute, University of the Sunshine Coast, 12 Innovation Parkway, Birtinya, QLD, 4575, Australia.
  • Abdalla Z Mohamed
    Thompson Institute, University of the Sunshine Coast, Birtinya, Australia.
  • Megan Dutton
    Thompson Institute, University of the Sunshine Coast, 12 Innovation Parkway, Birtinya, QLD, 4575, Australia.
  • Daniel F Hermens
    Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
  • Vince D Calhoun
    Mind Research Network & Lovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico; Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, New Mexico; Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, New Mexico; Department of Neurosciences, University of New Mexico, Albuquerque, New Mexico.
  • Leanne M Williams
    Stanford Center for Precision Mental Health and Wellness, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.
  • Maxwell Bennett
    University of Sydney, Sydney, NSW, 2006, Australia.
  • Jim Lagopoulos
    Thompson Brain and Mind Healthcare, 55 Plaza Parade, Maroochydore, QLD, 4558, Australia.